Codexis (CDXS) Cash & Current Investments (2010 - 2026)
Codexis' (CDXS) quarterly Cash & Current Investments came in at $65.1 million in Q1 2026, up 8.9% year-on-year from $59.8 million in Q1 2025, and down 16.71% quarter-over-quarter from $78.2 million in Q4 2025.
Codexis (CDXS) Cash & Current Investments (2010 - 2026) Analysis & Trends
Codexis' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $65.1 million for Q1 2026.
- On a quarterly basis, Cash & Current Investments rose 8.9% year-over-year to $65.1 million in Q1 2026; TTM through Mar 2026 was $65.1 million, a 8.9% increase from a year earlier, with the FY2025 full-year figure at $78.2 million, up 6.46% from the prior year.
- Cash & Current Investments retreated to $65.1 million in Q1 2026 per CDXS's latest filing, from $78.2 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $114.0 million in Q4 2022 and bottomed at $2.1 million in Q1 2022.
- The 5-year median for Cash & Current Investments is $66.3 million (2025), against an average of $70.0 million.
- Biggest YoY gain for Cash & Current Investments was 5075.67% in 2022; the steepest drop was 98.51% in 2022.
- Year by year, Cash & Current Investments stood at $114.0 million in 2022, then slumped by 42.87% to $65.1 million in 2023, then grew by 12.82% to $73.5 million in 2024, then grew by 6.46% to $78.2 million in 2025, then retreated by 16.71% to $65.1 million in 2026.
- Per Business Quant, the three latest CDXS Cash & Current Investments figures stand at $65.1 million (Q1 2026), $78.2 million (Q4 2025), and $58.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,320.50 Bn | 66,320.21 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.93 Bn | 468.14 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.22 Bn | 114.98 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.96 Bn | 61.21 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.66 Bn | 62.66 Bn | - | - |
| 8 | Argenx Se | 56.07 Bn | 50.89 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.60 Bn | 34.59 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Codexis | 140.24 Mn | 75.10 Mn | 13.18 Mn | 65.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 65.14 Mn |
| Dec 31, 2025 | 78.21 Mn |
| Sep 30, 2025 | 58.75 Mn |
| Jun 30, 2025 | 66.33 Mn |
| Mar 31, 2025 | 59.82 Mn |
| Dec 31, 2024 | 73.46 Mn |
| Sep 30, 2024 | 54.38 Mn |
| Jun 30, 2024 | 56.18 Mn |
| Mar 31, 2024 | 29.08 Mn |
| Dec 31, 2023 | 65.12 Mn |
| Sep 30, 2023 | 74.58 Mn |
| Jun 30, 2023 | 92.09 Mn |
| Mar 31, 2023 | 102.83 Mn |
| Dec 31, 2022 | 113.98 Mn |
| Sep 30, 2022 | 108.69 Mn |
| Jun 30, 2022 | 90.11 Mn |
| Mar 31, 2022 | 2.09 Mn |
| Dec 31, 2021 | 116.80 Mn |
| Sep 30, 2021 | 2.10 Mn |
| Jun 30, 2021 | 2.10 Mn |